Promethera raises €39.7mm through Series D round; closes round at €47.2mm
Promethera Biosciences SA NV raised €39.7mm ($44.4mm) through its Series D round. Itochu Corp. co-led the round with a €10mm investment, along with Shinsei Capital Partners, and the pair were joined by additional buyers Medipal Holdings, Mirae Asset Capital, the family office Six Snow, Korea Investment Partners, Ci:z Investment LLP, Mitsui & Co., and Belgian private investors. Proceeds will support Promethera's HepaStem cell technology platform (liver-derived stem cells from healthy donated organs and expanded in a lab) for acute-on-chronic liver failure (ACLF) and initiation of a clinical trial in NASH.
|Promethera announced that it received a final closing of €7.5mm ($8.36mm), bringing the Series D total of €47.2mm. New investors Sony Innovation Fund by IGV and Pegasus Tech Ventures led the tranche. New proceeds will be used to advance NASH and acute-on-chronic liver failure candidates, and accelerate the company's growth in Asian markets.|
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com